Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
- Written by: ACN Newswire - Press Releases
Read more //?#
.
-phase-2b-clinical-trial-in-early-alzheimer-s-disease&media=https://businessdailymedia.com/http://www.acnnewswire.com/images/company/Eisai.jpg&description=Eisai:%2018-Month,%20Pre-Specified%20Analysis%20Showing%20Consistent%20Reduction%20in%20Clinical%20Outcome%20Measures%20from%20a%20Lecanemab%20(BAN2401)%20Phase%202b%20Clinical%20Trial%20in%20Early%20Alzheimer's%20Disease "Pin It")
Gift Cards as the gateway to agentic payments
Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...
Why Data Accumulation Without Governance Undermines Sustainability Goals
In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...
Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty
The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...
Selling a Small Business in Australia: Understanding the Capital Gains Tax Concessions
For many Australian business owners, selling a business represents the reward for years—sometimes decades—of hard work. Unlike employees who may bu...
Australian businesses lean into global strategic partnerships (GCCs) for next wave of outsourcing
The Australian corporate landscape is undergoing a fundamental transformation in how it sources talent and innovation. While businesses have traditi...
The New Pressure Gap Crushing Small Businesses
Starting any business and making it prosper is a major undertaking. Part of the challenge is managing the uncertainty, but the financial pressures o...